Matthew R. Cooperberg, MD, MPH
The utilization of active surveillance and prostate-specific antigen (PSA) screening has continued to shift in the recent years, particularly following call-to-actions with the updated recommendations from the US Preventive Services Task Force (USPSTF), ASCO prostate cancer screening guidelines, and the collaborative AUA/ASTRO/SUO guidelines.
State of the Science SummitTM on Genitourinary Cancers, Cooperberg, an associate professor of urology and Helen Diller Family Chair in Urology at the University of California, San Francisco (UCSF) School of Medicine, discussed the benefits associated with active surveillance for patients with low-risk prostate cancer, as well as the development of personalized medicine.
OncLive: Can you please provide an overview of your presentation of prostate cancer screening?
It is increasingly clear that prostate cancer screening saves thousands of lives but at the expense of overdiagnosis and overtreatment. There is a growing consensus that screening makes sense but in the context of targeting treatments only for the patients who are going to benefit.
... to read the full story